Rare Disease Launch: Vendor Stack Playbook

Rare disease launches do not look like other specialty launches. Patient populations drop from hundreds of thousands to hundreds, prescribing concentrates among a handful of KOLs, list prices climb into six and seven figures, and distribution shrinks to one or two specialty pharmacies. The vendor stack that supports a mass-market specialty launch — broad hub, multi-SP network, thousand-rep field force, national copay card — is the wrong stack for rare disease.

This playbook is written for the VP Commercial Ops at a 50-person biotech preparing a first-in-class orphan launch. It walks the exact vendor decisions your team faces, in sequence, with named vendors, pricing benchmarks, and the trade-offs that matter. It assumes you know your disease and clinical story, and you now need to build the commercial infrastructure that gets drug to patient.

---

Why Rare Disease Launches Are Different

About half of recent CDER novel drug approvals carry orphan designation, the rare disease market is growing quickly, and global rare disease drug sales are projected to exceed $300B by 2028. But the commercial mechanics differ from standard specialty in ways that reshape every vendor decision.

Ultra-small patient populations. Orphan designation covers diseases affecting fewer than 200,000 U.S. patients. Ultra-orphan drugs treat populations under 10,000, often under 1,000. A 500-patient launch cannot support a 75-FTE hub, a 50-rep field force, or a 10-pharmacy SP network. The vendor stack has to be sized for the population.

Patient finding is the gating problem. The average rare disease patient waits 5-7 years from symptom onset to correct diagnosis, sees 7-8 physicians, and may receive 2-3 incorrect diagnoses along the way. The undiagnosed population often outnumbers the diagnosed population by 2-5x. The commercial problem is finding patients whose claims history, lab values, or clinical notes suggest they meet label criteria but have never been correctly coded.

Limited distribution and product-specific safety controls are common. As of 2025, there are 382 specialty drugs in limited or exclusive distribution networks; 34% use a single exclusive pharmacy and another 34% use 2-4 pharmacies. Some rare-disease therapies also require REMS or other product-specific safety controls. LDD network design is a day-one decision.

Orphan drug pricing changes copay math. Annual treatment costs of $200K-$3M+ (gene therapy one-time prices reaching $4.25M) mean patient cost-sharing is effectively 100% first-dollar. Standard copay cards are insufficient. You need integrated PAP, foundation partnerships, and bridge supply infrastructure.

Payer engagement is case-by-case. Small populations mean payers often have no established clinical criteria at launch and may develop criteria through the first 10-20 PA submissions. Prior authorizations routinely run 50-150 pages. Medical exceptions and peer-to-peer reviews are standard, not exceptional.

Patient journeys are concierge-level. Rare disease hubs operate at 1:50 coordinator-to-patient ratios (versus 1:200-500 in standard specialty). Cases involve genetic counselors, social workers, travel coordinators, and caregiver support. PANTHERx Rare reports an average of 8 patient interactions before first dispense, up to 14 for complex therapies.

---

The Rare Disease Vendor Stack

Rare disease commercialization requires eight coordinated functions. Each has a distinct vendor landscape. Treating them as interchangeable with mass-market specialty vendors is the most common error and shows up as missed patient starts in the first six months post-launch.

1. Patient Identification and Finding

Patient finding is the highest-ROI investment in the stack. For a 500-patient drug, finding an additional 50 patients is a 10% revenue lift for roughly $100-500K in data and analytics spend.

Vendor	Approach	Best For Rare Disease
IQVIA Patient Finder	300M+ patient longitudinal claims; gold-standard data depth; integrated with prescriber targeting	Broad use across rare disease; default for large commercial analytics teams
Komodo Health Healthcare Map	330M+ lives; machine-learning patient journey analytics; more accessible platform	Modern alternative to IQVIA; strong for ultra-orphan diagnosis modeling
Symphony Health (IQVIA)	U.S. Rx/Dx claims; prescriber-level analytics	Complementary overlay for HCP targeting
Flatiron / Tempus	EHR-derived oncology data; genomic and NLP-enabled	Onco-rare (AML, multiple myeloma, rare tumor subtypes)
Invitae / GeneDx / Blueprint Genetics	Genetic testing labs	Manufacturer-sponsored free testing programs to identify confirmed-mutation patients

The recommended configuration is IQVIA or Komodo as primary claims-based patient finder, supplemented by a manufacturer-sponsored genetic testing program (Invitae, GeneDx) when the disease has a confirmed genetic marker. In onco-rare, add Flatiron or Tempus for EHR-derived genomic data.

One caveat: rare disease ICD-10 codes are notoriously imprecise. Both IQVIA and Komodo offer predictive models that identify likely undiagnosed patients based on symptom constellations — these matter more in rare disease than in standard specialty where diagnosis codes are reliable.

2. Hub Services and Patient Support

The hub is the operational spine. For rare disease, the question is whether you need a full-service rare disease boutique, a rare disease division of a large hub platform, or a best-of-breed pairing with an SP that has integrated hub capabilities.

Vendor	Type	Rare Disease Positioning
EVERSANA	Full-stack commercialization platform	EVERSANA COMPLETE is the default for emerging biotech; integrated hub + SP + 3PL + field + commercial analytics; highest vendor consolidation
Cencora / Lash Group	Major hub platform with rare disease programs	TrakCel CGT orchestration; legacy rare disease programs; note the 2026 strategic review of U.S. hub as non-core
ConnectiveRx	Dedicated hub platform (Kohlberg-owned)	Strong broad-hub capabilities; strongest copay administration in market; less rare-disease-specialized than boutiques
AssistRx	Hub + specialty pharmacy; PE-backed (WCAS)	Solid mid-market rare disease programs; iAssist platform strong on ePA
CareMetx	Hub services with tech focus	Used across rare disease; strong digital enrollment and ePA
RareMed Solutions	Rare disease boutique hub	RarePath Connect portal; ultra-orphan specialization; best for first-in-class orphan launches with no existing commercial infrastructure
Inizio Engage	Clinical nurse educator + rare disease heritage	25+ year rare disease presence; nurse navigator model; good for programs requiring deep in-field clinical support

Rare-disease-specific criteria that matter:

• Coordinator-to-patient ratio committed in writing (target 1:50 or better for ultra-orphan)
• Disease-specific case manager training (dedicated team, not cross-trained generalists)
• Caregiver support infrastructure (pediatric rare disease centers the caregiver as primary program participant)
• Patient registry integration (FDA post-marketing commitments routinely require registries)
• PA workflow for 50-150 page submissions (not 10-page standard PAs)
• Genetic testing program administration (if applicable)
• Bridge supply capability (free drug between enrollment and coverage)

For an emerging biotech with no prior hub relationship, EVERSANA COMPLETE or a rare disease boutique (RareMed, ConnectMed360) typically outperforms a custom program with a large generalist hub. Small-team vendor management economics favor integrated full-stack over best-of-breed at the sub-500-patient tier.

3. Specialty Pharmacy and LDD Network Design

SP selection is the single most consequential vendor decision in a rare disease launch. It determines where your data comes from, how patients experience the drug, and how defensible your channel is over time.

Vendor	Scale	Rare Disease Strength	Best For
PANTHERx Rare	$1B+ revenue; Drug Channels #7 SP; 40+ orphan drugs	Gold-standard rare disease pharmacy; dual URAC + ACHC accreditations; RxARECARE patient model with 8 pre-dispense interactions	Default choice for traditional rare disease; strongest brand validation (8x MMIT Patient Choice Award)
Orsini Specialty Pharmacy	~$350-500M revenue; 35+ LDDs; 12 CGTs	Largest CGT portfolio in industry; integrated hub + SP + 3PL; DMD franchise depth; ORBIT AI platform	Cell/gene therapy launches; manufacturers wanting a single integrated partner
Accredo (Evernorth)	Largest U.S. SP overall	GeneAXS gene therapy program; rare disease programs within generalist portfolio; PBM affiliation	Larger rare disease programs needing payer network breadth
CVS Specialty	PBM-affiliated; broad LDD access	Gene therapy Center for Innovation Technology (GCIT); claims more gene therapy LDD launches than any other SP	When PBM formulary positioning is decisive
McKesson Biologics	Distributor-affiliated	14% of exclusive-network drug positions	Manufacturers prioritizing distribution integration
Vanscoy Rare Pharmacy	Newer entrant (2024)	Founded by original PANTHERx team	Watch-list; not yet proven at scale

The core LDD design question: single-exclusive versus 2-3 pharmacy network.

Single-exclusive networks (34% of LDD drugs in 2025, up from 28% in 2022) maximize manufacturer control, data capture, clinical protocol consistency, and pharmacy leverage. The trade-off is concentration risk: one operational failure, one REMS incident, and patients lose access. PANTHERx-exclusive and Orsini-exclusive configurations are common for ultra-orphan drugs.

2-3 pharmacy networks balance data concentration with risk mitigation and payer network breadth. Adding Accredo or CVS Specialty to a PANTHERx or Orsini exclusive extends access to PBM-steered patients. For 500-10,000 patient rare disease drugs, a 2-pharmacy configuration (specialized rare disease SP + PBM-affiliated SP) is increasingly common.

A Vanderbilt study found LDD drugs take a mean 6 days from treatment decision to shipment versus 3 days for non-LDD drugs. LDD design should include contractual SLAs on time-to-fill.

4. Market Access, GTN, and Payer Strategy

Rare disease market access is distinct because small populations mean less PBM formulary leverage. Core access work shifts from winning formulary positions to preparing for case-by-case medical exceptions. The vendor must build the clinical narrative, budget impact model, HTA dossier, and payer-specific value proposition for what will be individual medical director conversations.

Vendor	Type	Rare Disease Fit
Trinity Life Sciences	Pure-play commercial strategy; rare disease practice	Strong HEOR and payer value communication; often engaged at T-18+ for launch strategy
Precision AQ	Launch consulting and market access; rebranded from Precision Value & Health	Broad launch strategy with rare disease capability
Lumanity	Integrated insight-to-activation platform	HEOR and real-world evidence focus
IQVIA Market Access	Data-integrated market access	Strong when patient finding and market access are bundled
Avalere Health	Policy and payer strategy	Strong on policy-driven coverage (Medicare Part B/D, state Medicaid)
Xcenda (Cencora)	Market access consulting	Formulary strategy and payer communication

Trinity Life Sciences is the most commonly cited pure-play rare disease market access partner. Precision AQ and Lumanity are strong integrated alternatives. IQVIA Market Access is the default when patient finding and market access are bundled.

When to engage: Start at T-18 months, before pricing decisions. Deliverables are a payer landscape assessment, HEOR strategy, budget impact model, value proposition by payer archetype, and launch pricing recommendation with GTN modeling. Engaging at T-9 or later means launching without the analytical foundation to defend your price.

5. Copay and Financial Assistance

At rare disease price points, copay economics invert. A $300K/year drug with a $10,000 OOP max means the manufacturer effectively provides 97%+ of patient cost support. For Medicare patients (federal anti-kickback rules prohibit manufacturer copay), foundation assistance is the only path. For uninsured patients, PAP (free drug) is the answer.

Vendor	Role	Rare Disease Use
ConnectiveRx	Copay card administration; 71% gross margin copay business	Primary copay administrator for rare disease when copay cards are the vehicle
Hub vendor integrated copay	EVERSANA, Lash Group, CareMetx all administer copay internally	Common for integrated stack decisions
HealthWell Foundation	Independent charitable foundation	Critical for Medicare patients; disease-specific funds where available
PAN Foundation	Independent charitable foundation	Complements HealthWell for broader disease coverage
NORD (National Organization for Rare Disorders)	Advocacy + copay assistance	Disease-specific relief funds
Accessia Health	Independent charitable foundation	Copay assistance for Medicare and commercial
Patient Advocate Foundation	Patient navigation and assistance	Bridge navigation services; copay relief
TailorMed	AI-powered financial navigation	Identifies all available assistance across sources

The typical rare disease financial assistance stack:

• Manufacturer copay card ($10,000-$50,000+ annual value per patient) via ConnectiveRx or hub
• PAP for uninsured patients; 15-30% of rare disease patients may receive free drug at some point
• Foundation partnerships (HealthWell, PAN, Accessia, disease-specific foundations) for Medicare and uncovered commercial patients
• Bridge supply during BI and PA processing
• Accumulator/maximizer mitigation (~39% of commercial lives are in plans with active accumulators as of late 2025)

Foundation architecture is where many rare disease launches get it wrong. Medicare anti-kickback rules prohibit manufacturer copay for Medicare patients, and disability-qualification plus age 65+ captures many progressive genetic diseases. NORD, HealthWell, and PAN operate per-disease-fund models — a fund for your disease may or may not exist with capacity. Engage at T-12 to T-9.

6. Field Force and FRMs

Rare disease field forces are small. A 50-rep launch is wasteful when 50 prescribers exist in the entire U.S. Standard configuration: 1-10 territory reps plus 2-5 Field Reimbursement Managers (FRMs).

Option	Best For	Economics
In-house hire	Launches with long-tail revenue; teams intending to build sustained rare disease commercial capability	$150-250K fully loaded per territory; 6-9 month recruit and ramp
Contract sales organization (CSO)	Launches under 5 territories; first-time rare disease companies; short-term needs	Comparable per-rep cost; faster ramp (60-90 days); preserves optionality
Inizio Engage, Syneos, Ashfield, EVERSANA Field Solutions	CSOs with rare disease track record	Wrap field force with nurse educator and medical liaison services
FRM-only model (no reps)	Ultra-orphan with fewer than 50 total prescribers	MSL handles scientific exchange; FRM handles reimbursement; no traditional sales rep

For a 500-patient launch with 20-50 concentrated prescribers, the rational configuration is often 3-5 FRMs, 2-3 MSLs, and no traditional sales reps. The FRM is the workhorse: handling account-level reimbursement support, coordinating with hub staff on individual patients, and serving as liaison between prescriber office and commercial.

Build-versus-buy favors CSO below 5 territories. Above 10 territories with portfolio intent, in-house dominates.

7. Medical Affairs and KOL Engagement

Medical affairs is the center of gravity in rare disease. In ultra-orphan disease with 10-50 global KOLs, the same individuals who ran the pivotal trials, wrote guidelines, and edit the journals are the actual treating physicians. The commercial model is MSL-driven relationship cultivation, not reach-and-frequency.

MSL headcount typically runs 2-8 for ultra-orphan and 5-15 for broader rare disease. Most biotechs build MSL teams in-house; outsourced MSLs via Syneos Commercial Solutions or Inizio Medical exist but are less common because relationship capital is core to commercial durability.

8. Advocacy and Patient Groups

Patient advocacy organizations are not vendors but are mission-critical partners — often the primary source of patient finding (many maintain registries), the leading voice in payer coverage decisions, and informal channels for RWE. Core relationships: NORD (umbrella + assistance funds + state policy); disease-specific foundations (every rare disease has 2-4 meaningful ones); Global Genes; EveryLife Foundation. Engagement starts in clinical development and deepens at T-18. Most biotechs designate a patient advocacy lead reporting into medical affairs rather than outsourcing.

---

Launch Timeline: T-18 to T+6

Implementation windows are long (hub builds 5-7 months, SP onboarding 3-6 months, market access 12+ months). Running them sequentially compresses go-live and creates operational risk. Use this as a default and adjust for your PDUFA.

Timing	Vendor Function	Activity
T-18 to T-15	Market access consulting	Engage Trinity Life Sciences, Precision AQ, or Lumanity; begin payer landscape, HEOR, budget impact, and value proposition work
T-18 to T-15	Patient finding / RWE	Engage IQVIA or Komodo; begin addressable population estimation, diagnosis pattern analysis, and HCP concentration mapping
T-18	Advocacy strategy	Formalize NORD relationship and build engagement plan with 2-4 disease-specific foundations
T-15 to T-12	Hub RFP	Issue RFP; target 3-5 shortlisted vendors; aim for contract execution by T-10
T-12 to T-9	Specialty pharmacy LDD design	Select 1-3 SPs; PANTHERx, Orsini, Accredo, or CVS Specialty depending on configuration; negotiate exclusive terms if applicable
T-12	Foundation engagement	Engage HealthWell, PAN, and disease-specific foundations on fund creation, capacity planning, and eligibility design
T-12 to T-9	Medical affairs build	Begin MSL hiring; formalize KOL map; plan advisory boards
T-10	Hub contract execution	Begin 5-7 month implementation
T-9 to T-6	Copay and PAP program design	Design manufacturer copay card; design PAP eligibility criteria; integrate with hub
T-9 to T-6	Field force decision	Commit to in-house vs. CSO; begin FRM hiring or CSO contract execution
T-6 to T-3	Hub and SP systems integration testing	Mock patient journeys; end-to-end testing of enrollment, BV, PA, copay, fulfillment
T-6	REMS program launch prep (if applicable)	UBC or Invaryant REMS administration; prescriber and pharmacy certification workflows
T-3 to T-1	Launch readiness	Hub training complete; SP LDD network live; field force deployed; copay and PAP live; foundation funds ready
T-0	Launch	All systems live
T+1 to T+3	Patient experience monitoring	Hub call center stability; PA approval rates; time-to-fill; patient abandonment signals
T+3 to T+6	Optimization	Iterate on PA workflows; refine HCP targeting based on first enrollments; expand foundation capacity if needed

Mission-critical milestones: Hub contract by T-10 (later risks going live with a partial program). SP LDD network live by T-3 (testing under 90 days is operationally risky). Market access engaged by T-15 (later means launching without defensible pricing foundation). Foundation engagement by T-9 (disease-specific funds may need fundraising cycles to build capacity).

---

Key Trade-offs

Rare disease vendor strategy reduces to four recurring trade-offs.

Single-SP exclusive versus 2-3 pharmacy LDD. Exclusive maximizes control, data capture, and consistency but concentrates risk. For ultra-orphan, exclusive is default. For 10,000+ patient programs where payer network breadth matters more, 2-3 pharmacy networks are increasingly common. A fallback SP relationship — even inactive — is cheap insurance.

Full-stack versus best-of-breed. EVERSANA COMPLETE, Cencora/Lash Group, and IQVIA each offer end-to-end. For an emerging biotech with a single drug, full-stack wins on small-team economics: one procurement, one implementation, one relationship. For portfolio ambitions, best-of-breed (PANTHERx + ConnectiveRx + Trinity + Komodo) wins on depth, data ownership, and optionality. Inflection point: roughly the second product or the 3,000-patient mark.

Build versus buy for FRMs. Under 5 territories, CSO wins on speed. Above 10 territories with portfolio intent, in-house wins on relationship capital. The 5-10 territory middle ground depends on therapeutic continuity.

Foundation copay under IRA. The IRA’s redesigned Part D (with a $2,000 OOP cap in 2025) shifts cost to plans, but manufacturers still cannot support Medicare copay. Foundations become the primary Medicare vehicle. Designing foundation architecture — which funds exist, whose capacity can scale, how eligibility criteria align — is a T-12 decision, not T-3. Teams that treat foundations as an afterthought discover at launch that capacity does not exist for their disease.

---

Pricing Benchmarks for Rare Disease

Rare disease vendor pricing is less standardized than mass-market specialty. Public benchmarks are scarce, hub pricing is opaque by design, and contract structures vary from FTE-based to transaction-based to bundled. The ranges below are directional; acknowledge uncertainty and get vendor-specific proposals before committing.

Function	Typical Range	Drivers	Notes
Hub services (ultra-orphan, <1,000 patients)	$1M-$3M annual	FTE count (10-25); therapeutic complexity; scope (hub-only vs. hub + clinical + nurse)	Generally FTE-based pricing; $50-65K loaded per FTE
Hub services (rare disease, 1,000-10,000 patients)	$3M-$8M annual	FTE count (25-75); scope expansion	Hybrid pricing (FTE + per-transaction) more common
Specialty pharmacy (LDD exclusive)	Bundled	Dispensing fees + data fees + service fees; some manufacturer rebate structures	Often no separate SP fee; economics built into channel margin; PANTHERx and Orsini are “data as service” partners
Specialty pharmacy (multi-SP network)	Per-dispense fees	Volume-based pricing	More transparent but less data concentration
Field force (per territory in-house)	$150-250K annual	Rep comp + benefits + management overhead; travel	Comparable for FRM and rep roles
Field force (CSO)	$150-250K per seat, often with multi-year premium	Comparable to in-house but faster ramp	Syneos, Ashfield, Inizio, EVERSANA Field Solutions
Market access consulting	$300K-$800K for launch strategy	Scope (landscape vs. launch vs. HEOR vs. global HTA)	Trinity, Precision AQ, Lumanity; engagement typically 6-9 months
Patient finding / RWE	$100K-$500K annual	Data license + analytics service; customization	IQVIA typically higher end; Komodo more accessible entry point
Medical affairs (MSL team)	$300-500K per MSL annual	Loaded comp + travel; typically in-house	2-8 MSLs for ultra-orphan
Copay card administration	Per-redemption fees (~$2-5) + fixed program fees	Volume-driven	ConnectiveRx is the scale leader at ~$2.50 per redemption
Foundation contributions	Variable; disease-fund dependent	Manufacturer donations to independent foundations per OIG compliance framework	Legal structure requires arms-length; cannot direct to specific patients
REMS administration (if applicable)	$500K-$1M+ annual	Complexity of ETASU; prescriber and pharmacy certification volumes	UBC, Invaryant are major administrators

Total launch services budget: Under-500-patient programs typically run $5-15M across the T-18 to T+12 cycle, with hub and SP accounting for roughly half and market access, patient finding, field, medical affairs, and foundation contributions splitting the balance. Larger rare disease (10,000+ patients) can reach $20-30M+.

One pattern worth flagging: first-year hub costs typically run 20-30% above steady state due to implementation, staffing ramp, and training. Budget for this front-loading.

---

Red Flags to Avoid

Eight signals that should eliminate a candidate or trigger contractual protections:

• Hubs without rare disease case management depth. Coordinator-to-patient ratios of 1:200 and cross-trained generalists cannot support ultra-orphan journeys. Require dedicated FTE commitment in writing.
• SPs without cryogenic capability (if CGT). Orsini, PANTHERx RxARECONCIERGE, and CVS Specialty GCIT have validated capability. A generalist SP with “we can do that” is a red flag.
• Market access without rare disease HTA experience. Ask for named rare disease engagements, not therapeutic area breadth claims.
• Single-LDD without contingency. Build a contractual fallback — even pre-qualified inactive — before go-live.
• Hubs or SPs without named rare disease references. Inability to identify 2-3 rare disease manufacturer clients signals lack of depth.
• Copay vendors without accumulator/maximizer strategy. ~39% of commercial lives are in plans with active accumulators. “We monitor it” is insufficient.
• Vendors who will not commit to data ownership and portability. Non-negotiable.
• Vendors in unstable ownership cycles. PANTHERx (2026-2028) and Orsini (2027-2029) are in PE exit windows; Cencora signaled potential U.S. hub divestiture in Q1 FY2026. Change-of-control provisions should be explicit with 6-month written notice and termination rights on material ownership change.

---

Example Stack Configurations

Ultra-Orphan (50-500 Patients) — first-in-class orphan, single indication, traditional therapy

Function	Vendor	Rationale
Hub	EVERSANA COMPLETE	Full-stack reduces vendor count; rare disease launch specialty
Specialty Pharmacy	PANTHERx Rare (exclusive LDD)	Gold standard for traditional rare disease; strongest brand and patient outcomes
Market Access	Trinity Life Sciences	Pure-play rare disease market access
Patient Finding	Komodo Health + sponsored genetic testing (if applicable)	Modern claims analytics + genetic confirmation
Copay + PAP	Integrated via EVERSANA; foundation partnerships with HealthWell + NORD	Consolidates financial assistance
Field Force	3-5 FRMs via CSO (Inizio Engage or Syneos); no territory reps	50-patient population does not require traditional reps
Medical Affairs	2-3 MSLs in-house	Long-term relationship capital stays inside the company

Estimated total commercial services spend: $5-10M over the T-18 to T+12 cycle.

Small Rare (500-10,000 Patients) — rare disease drug, 1-2 indications, standard specialty distribution

Function	Vendor	Rationale
Hub	ConnectiveRx or Cencora/Lash Group	Best-of-breed hub with rare disease depth; alternative to full-stack
Specialty Pharmacy	Orsini (exclusive or primary) + Accredo (secondary for PBM network)	Integrated hub+SP+3PL plus broad payer access
Market Access	Trinity + Lumanity for HEOR	Layered approach with HEOR specialization
Patient Finding	Komodo (primary) + IQVIA (overlay for HCP targeting)	Dual-source approach for a larger undiagnosed population
Copay + PAP	ConnectiveRx copay (per-redemption) + integrated PAP + foundation partnerships	Scale leader on copay economics
Field Force	5-10 FRMs in-house + 2-5 territory reps (CSO initially, in-house over time)	Justifies sales presence at this scale
Medical Affairs	5-8 MSLs in-house	Broader KOL network

Estimated total commercial services spend: $10-20M over the T-18 to T+12 cycle.

Larger Rare (10,000-50,000 Patients) — larger addressable population; 2+ indications or follow-on assets

Function	Vendor	Rationale
Hub	ConnectiveRx or Cencora/Lash Group (best-of-breed)	Requires scale of generalist hub with rare disease carveout
Specialty Pharmacy	3-SP network: PANTHERx or Orsini (primary) + Accredo + CVS Specialty	Breadth required for PBM network coverage
Market Access	Trinity (launch strategy) + Avalere (policy) + in-house market access team	Policy complexity at this scale
Patient Finding	IQVIA full suite (claims + prescriber targeting + Orchestrated Customer Engagement)	Scale and integrated activation
Copay + PAP	ConnectiveRx copay at scale + in-house PAP + foundation partnerships	Volume economics
Field Force	10-30 territory reps in-house (CSO to accelerate initial deployment) + 5-10 FRMs	Traditional sales model viable at this scale
Medical Affairs	10-15 MSLs in-house + advisory board infrastructure	Broader KOL and guideline engagement

Estimated total commercial services spend: $20-30M+ over the T-18 to T+12 cycle.

---

Related Resources

Category pages:

• Specialty Pharmacies
• Hub Services
• Market Access Consulting
• Copay and Financial Assistance

Vendor profiles:

• PANTHERx Rare
• Orsini Specialty Pharmacy
• EVERSANA
• ConnectiveRx
• Trinity Life Sciences
• IQVIA
• Komodo Health
• Cencora / Lash Group
• AssistRx
• CareMetx

Related articles:

• Hub Services Buyer’s Guide 2026 — complete hub RFP framework and evaluation
• Hub RFP Framework — 73-question RFP template
• Hub Services Platforms — platform landscape
• ConnectiveRx vs EVERSANA — specialist hub vs. integrated full-stack
• Market Access Consulting — market access vendor landscape
• Pharma Services Market Sizing — overall services market context
• Top Specialty Pharmacies for Pharma Manufacturers — SP vendor deep dive

---

Caveats

Figures are industry-sourced benchmarks for the rare disease services landscape. Use them as planning ranges, not contractual inputs:

• Hub pricing ranges are directional; vendor proposals vary by scope and terms.
• Patient population ranges are industry framing; the regulatory orphan threshold is 200,000 U.S. patients.
• Field territory costs ($150-250K) are benchmarks; CSO vs. in-house economics vary by geography.
• Total launch services budgets ($5-15M ultra-orphan; $20-30M larger rare) are directional; programs can deviate significantly based on REMS, CGT status, global scope, and company maturity.
• Foundation capacity varies by disease; engage HealthWell, PAN, Accessia, and disease-specific foundations early and directly.
• PE exit windows cited (PANTHERx 2026-2028; Orsini 2027-2029) reflect 2022 sponsor acquisitions and typical 4-6 year hold periods; timing will evolve.

Validate all vendor-specific numbers through RFP and direct reference checks. This playbook is a decision framework, not a substitute for vendor-specific diligence.